What are PEG Linkers?

Polyethylene glycol or PEG-linkers are particularly attractive as a linker for conjugation due to their water solubility, lack of toxicity and low immunogenicity. PEG linkers have been widely used in pharmaceutical and biotech applications such as protein and peptide PEGylation, antibody drug conjugation (ADC), drug delivery and surface modifications.

Unlike traditional PEGs, BroadPharm’s PEG linkers represent a specific, single pure chemical structure with high purity. Each product is synthesized and purified using BroadPharm’s proprietary technology and characterized by modern NMR and LC/MS. BroadPharm offers over thousands of PEG linkers, Click Chemistry tools and water soluble fluorescent reagents which can empower your drug research and development, by improving drug solubility and stability, optimizing DMPK or discovering new drug delivery formats.

Our high-quality PEG linkers are water soluble, monodisperse, biocompatible, and almost aggregation-free, making them ideal for bioconjugation or crosslinking of proteins, antibodies, peptides, oligonucleotides, or solid surfaces to other molecules. Explore the use of different functional groups of PEG Linkers and Click chemistry approaches. Choose from linear, branched, or heterobifunctional PEGylation reagents with your preferred PEG length - PEG linkers products are provided as single-molecular-weight species. Not sure which compound is best or needing a customized compound? Talk to our scientists, who can provide expert support. Call 858-677-6760 or email sales@broadpharm.com. Find the desired PEG linkers that’s just right for your project – PEG Linkers. Recent review articles with PEG applications:

  1. Effect of Short PEG on Near-Infrared BODIPY-Based Activatable Optical Probes, Fuyuki F. Inagaki, Daiki Fujimura, et al., ACS Omega 2020 5 (25), 15657-15665.

  2. PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs, Peter L. Turecek, Mary J. Bossard, et al., Journal of Pharmaceutical Sciences 2016 2 (105), 460-475.

  3. Conjugation Strategy Strongly Impacts the Conformational Stability of a PEG-Protein Conjugate, Paul B. Lawrence, Wendy M. Billings, et al., ACS chemical biology 2016 11 (7), 1805-1809.

  4. Ligand Density and Linker Length are Critical Factors for Multivalent Nanoparticle–Receptor Interactions, Kathrin Abstiens, Manuel Gregoritza, et al., ACS Applied Materials & Interfaces 2019 11 (1), 1311-1320.

  5. Understanding the Stealth Properties of PEGylated lipids: A Mini-Review, Poornima Kalyanram, Anu Puri, et al., International Journal of Lipids 2020 1 (2), xxx-xxx.

  6. Antibody drug conjugates: lessons from 20 years of clinical experience, Anthony W. Tolcher, Annals of Oncology 2016 27 (12), 2168-2172.  

  7. Current strategies for the design of PROTAC linkers: a critical review, Robert I. Troup, Charlene Fallan, et al., Explor Target Antitumor Ther. 2020 1, 273-312.